Anyone got views on what the appointment of RFK means for health stocks. Not the big ones who I feel will be under pressure but the drug developers. Seemed to be a bit of a sell off last week. Cant but think that with FDA to be reduced in size that the whole testing protocol will be longer from trial design to approvals ( not to mention whatever web based ideas that take his fancy.)
